Qlife Holding AB (FRA:4HG0) FFO


FRA:4HG0 Qlife Holding AB FRA:4HG0
25 GF Score
Price €0.15
GF Value €0.06
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Qlife Holding AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:4HG0
25GF Score
Qlife Holding AB FRA:4HG0
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Qlife Holding AB (FRA:4HG0) Overvalued in 2026?

Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued. The current stock price of €0.15 is trading 144.7% above its estimated GF Value™ of €0.06. GuruFocus considers Qlife Holding AB to be Significantly Overvalued.

Key valuation signals for FRA:4HG0:

  • FFO:
  • GF Value™: €0.06 vs. price of €0.15 (144.7% above fair value)
  • GF Score™: 25/100 with 9 warning signs

No single metric tells the full story. See the FRA:4HG0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Qlife Holding AB Business Description

Other Exchanges QLIFE:Sweden
Address Nellikevagen 22, Goteborg, SWE, SE-412 63
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
25GF Score

Get the complete analysis for FRA:4HG0

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.06
GF Value